Literature DB >> 17070234

Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.

Andrew J Stephenson1, Raanan Tal, Joel Sheinfeld.   

Abstract

PURPOSE: Patients with metastatic testicular cancer with residual masses encasing the renal hilum or kidney after platin based chemotherapy may require adjunctive nephrectomy to achieve complete resection at post-chemotherapy retroperitoneal lymph node dissection. We reviewed our experience with adjunctive nephrectomy to assess the impact on cancer control and renal function.
MATERIALS AND METHODS: Of 647 post-chemotherapy retroperitoneal lymph node dissection procedures performed at our institution since 1989 adjunctive nephrectomy has been performed in 32 patients (5%). Patient information was obtained from a prospective database. Median followup was 31 months.
RESULTS: Of the adjunctive nephrectomy procedures 17 (53%) were performed in high risk settings such as post-salvage chemotherapy, desperation retroperitoneal lymph node dissection, late relapse and reoperative retroperitoneal lymph node dissection. Disease was present in the adjunctive nephrectomy specimen in 21 patients (66%). Following post-chemotherapy retroperitoneal lymph node dissection 7 patients had disease relapse and 5-year disease-free survival was 66%. No case of relapse required substitution for cisplatin due to compromised renal function. Progression to chronic renal insufficiency occurred in 3 patients, 1 of whom required hemodialysis. The calculated creatinine clearance after adjunctive nephrectomy was more than 30% below the age specific norm in 14 patients (50%) and median patient age was 40 years.
CONCLUSIONS: Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection is most frequently performed in patients with high risk features to ensure the completeness of resection. When indicated, adjunctive nephrectomy should be performed because residual cancer is frequently present and long-term cancer control can be achieved in 66% of patients. Although adjunctive nephrectomy did not interfere with subsequent chemotherapy, the renal reserve in these patients was substantially reduced in 50%, emphasizing the importance of preventative measures to preserve long-term renal function.

Entities:  

Mesh:

Year:  2006        PMID: 17070234     DOI: 10.1016/j.juro.2006.07.050

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  [Management of complications after residual tumor resection for metastatic testicular cancer].

Authors:  A Lusch; M Zaum; C Winter; P Albers
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

Review 2.  Residual tumor resection (RTR).

Authors:  A Lusch; P Albers
Journal:  World J Urol       Date:  2016-12-21       Impact factor: 4.226

3.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

Review 4.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 5.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

Review 6.  Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer.

Authors:  Patrick A Kenney; Ingolf A Tuerk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

7.  Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.

Authors:  Liam C Macleod; Saneal Rajanahally; Jasmir G Nayak; Brodie A Parent; Jorge D Ramos; George R Schade; Sarah K Holt; Atreya Dash; John L Gore; Daniel W Lin
Journal:  Urology       Date:  2016-01-21       Impact factor: 2.649

8.  Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.

Authors:  Axel Heidenreich; David Pfister
Journal:  Ther Adv Urol       Date:  2012-08

Review 9.  Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Authors:  Costantine Albany; Kenneth Kesler; Clint Cary
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075

10.  [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].

Authors:  P Paffenholz; D Pfister; A Heidenreich
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.